BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 38169047)

  • 1. A deep learning model integrating multisequence MRI to predict EGFR mutation subtype in brain metastases from non-small cell lung cancer.
    Li Y; Lv X; Chen C; Yu R; Wang B; Wang D; Hou D
    Eur Radiol Exp; 2024 Jan; 8(1):2. PubMed ID: 38169047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting EGFR T790M Mutation in Brain Metastases Using Multisequence MRI-Based Radiomics Signature.
    Li Y; Lv X; Wang B; Xu Z; Wang Y; Sun M; Hou D
    Acad Radiol; 2023 Sep; 30(9):1887-1895. PubMed ID: 36586758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinguishing EGFR mutation molecular subtypes based on MRI radiomics features of lung adenocarcinoma brain metastases.
    Xu J; Yang Y; Gao Z; Song T; Ma Y; Yu X; Shi C
    Clin Neurol Neurosurg; 2024 May; 240():108258. PubMed ID: 38552362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiomics signature of brain metastasis: prediction of EGFR mutation status.
    Wang G; Wang B; Wang Z; Li W; Xiu J; Liu Z; Han M
    Eur Radiol; 2021 Jul; 31(7):4538-4547. PubMed ID: 33439315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiregional radiomics of brain metastasis can predict response to EGFR-TKI in metastatic NSCLC.
    Fan Y; Wang X; Dong Y; Cui E; Wang H; Sun X; Su J; Luo Y; Yu T; Jiang X
    Eur Radiol; 2023 Nov; 33(11):7902-7912. PubMed ID: 37142868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brain-Tumor Interface-Based MRI Radiomics Models to Determine EGFR Mutation, Response to EGFR-TKI and T790M Resistance Mutation in Non-Small Cell Lung Carcinoma Brain Metastasis.
    Fan Y; Wang X; Yang C; Chen H; Wang H; Wang X; Hou S; Wang L; Luo Y; Sha X; Yang H; Yu T; Jiang X
    J Magn Reson Imaging; 2023 Dec; 58(6):1838-1847. PubMed ID: 37144750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiparametric MRI-Based Radiomics Approaches for Preoperative Prediction of EGFR Mutation Status in Spinal Bone Metastases in Patients with Lung Adenocarcinoma.
    Jiang X; Ren M; Shuang X; Yang H; Shi D; Lai Q; Dong Y
    J Magn Reson Imaging; 2021 Aug; 54(2):497-507. PubMed ID: 33638577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MRI radiomics for predicting intracranial progression in non-small-cell lung cancer patients with brain metastases treated with epidermal growth factor receptor tyrosine kinase inhibitors.
    Qu J; Zhang T; Zhang X; Zhang W; Li Y; Gong Q; Yao L; Lui S
    Clin Radiol; 2024 Apr; 79(4):e582-e591. PubMed ID: 38310058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diffusion tensor and postcontrast T1-weighted imaging radiomics to differentiate the epidermal growth factor receptor mutation status of brain metastases from non-small cell lung cancer.
    Park YW; An C; Lee J; Han K; Choi D; Ahn SS; Kim H; Ahn SJ; Chang JH; Kim SH; Lee SK
    Neuroradiology; 2021 Mar; 63(3):343-352. PubMed ID: 32827069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differentiating EGFR from ALK mutation status using radiomics signature based on MR sequences of brain metastasis.
    Li Y; Lv X; Wang B; Xu Z; Wang Y; Gao S; Hou D
    Eur J Radiol; 2022 Oct; 155():110499. PubMed ID: 36049410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiomics of Spinal Metastases Originating From Primary Nonsmall Cell Lung Cancer or Breast Cancer and Ability to Predict Epidermal Growth Factor Receptor Mutation/Ki-67 Levels.
    Niu S; Zhang H; Wang X; Jiang W
    J Comput Assist Tomogr; 2023 Jul-Aug 01; 47(4):643-649. PubMed ID: 37380152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preoperative MRI-Based Radiomics of Brain Metastasis to Assess T790M Resistance Mutation After EGFR-TKI Treatment in NSCLC.
    Fan Y; He L; Yang H; Wang Y; Su J; Hou S; Luo Y; Jiang X
    J Magn Reson Imaging; 2023 Jun; 57(6):1778-1787. PubMed ID: 36165534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MRI-based radiomics analysis for predicting the EGFR mutation based on thoracic spinal metastases in lung adenocarcinoma patients.
    Ren M; Yang H; Lai Q; Shi D; Liu G; Shuang X; Su J; Xie L; Dong Y; Jiang X
    Med Phys; 2021 Sep; 48(9):5142-5151. PubMed ID: 34318502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hybrid deep multi-task learning radiomics approach for predicting EGFR mutation status of non-small cell lung cancer in CT images.
    Gong J; Fu F; Ma X; Wang T; Ma X; You C; Zhang Y; Peng W; Chen H; Gu Y
    Phys Med Biol; 2023 Dec; 68(24):. PubMed ID: 37972417
    [No Abstract]   [Full Text] [Related]  

  • 15. Deep learning-radiomics integrated noninvasive detection of epidermal growth factor receptor mutations in non-small cell lung cancer patients.
    Kim S; Lim JH; Kim CH; Roh J; You S; Choi JS; Lim JH; Kim L; Chang JW; Park D; Lee MW; Kim S; Heo J
    Sci Rep; 2024 Jan; 14(1):922. PubMed ID: 38195717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MRI-Based Radiomics Nomogram as a Potential Biomarker to Predict the EGFR Mutations in Exon 19 and 21 Based on Thoracic Spinal Metastases in Lung Adenocarcinoma.
    Cao R; Dong Y; Wang X; Ren M; Wang X; Zhao N; Yu T; Zhang L; Luo Y; Cui EN; Jiang X
    Acad Radiol; 2022 Mar; 29(3):e9-e17. PubMed ID: 34332860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-liver interface in MRI of liver metastasis enables prediction of EGFR mutation in patients with lung cancer: A proof-of-concept study.
    Hou S; Wang H; Wang X; Chen H; Zhou B; Meng R; Sha X; Chang S; Wang H; Jiang W
    Med Phys; 2024 Feb; 51(2):1083-1091. PubMed ID: 37408393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting EGFR mutation status by a deep learning approach in patients with non-small cell lung cancer brain metastases.
    Haim O; Abramov S; Shofty B; Fanizzi C; DiMeco F; Avisdris N; Ram Z; Artzi M; Grossman R
    J Neurooncol; 2022 Mar; 157(1):63-69. PubMed ID: 35119589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined radiomics of primary tumour and bone metastasis improve the prediction of EGFR mutation status and response to EGFR-TKI therapy for NSCLC.
    Cheng Y; Wang H; Yuan W; Wang H; Zhu Y; Chen H; Jiang W
    Phys Med; 2023 Dec; 116():103177. PubMed ID: 38000098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiomics for the prediction of EGFR mutation subtypes in non-small cell lung cancer.
    Li S; Ding C; Zhang H; Song J; Wu L
    Med Phys; 2019 Oct; 46(10):4545-4552. PubMed ID: 31376283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.